Glioblastoma multiforme (GBM) is an aggressive brain cancer showing poor prognosis.
Currently, treatment methods of GBM are limited with adverse outcomes and low survival …

The current review focuses on the effect of phenothiazine derivatives, tested in vitro, on
necrosis and necroptosis, the latter constitutes one of the kinds of programmed cell death …

Glioblastoma (GBM) is the most prevalent and aggressive primary central nervous system
(CNS) malignancy. YM155 is a highly potent broad-spectrum anti-cancer drug that was …

Glioma is the most devastating high-grade tumor of the central nervous system, with dismal
prognosis. Existing treatment modality does not provide substantial benefit to patients and …

Peptide nanoassemblies have garnered remarkable importance in the development of novel
nanoscale biomaterials for drug delivery into tumor cells. Taking advantage of receptor …

Glioblastoma (GBM) is the most frequent and lethal brain tumor, whose therapeutic outcome-
only partially effective with current schemes-places this disease among the unmet medical …

Glioblastoma Multiforme (GBM) is the primary brain tumor and accounts for 200,000 deaths
each year worldwide. The standard therapy includes surgical resection followed by …

Glioblastoma multiforme (GBM) is an aggressive form of adult brain tumor that can arise from
a low-grade astrocytoma. In recent decades, several new conventional therapies have been …

Glioblastoma Multiforme (GBM) is a debilitating type of brain cancer with a high mortality
rate. Despite current treatment options such as surgery, radiotherapy, and the use of …

Background: The dysregulation of various pathways and cellular processes contributes to
the carcinogenic transition from low-grade gliomas to high-grade gliomas. The altered tumor …